These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 127559)

  • 21. A quantitative rotational model for studying serotonergic function in the rat.
    Jacobs BL; Simon SM; Ruimy DD; Trulson ME
    Brain Res; 1977 Mar; 124(2):271-81. PubMed ID: 139194
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Role of ventral mesencephalic reticular formation and related noradrenergic and serotonergic bundles in turning behaviour as investigated by means of kainate, 6-hydroxydopamine and 5,7-dihydroxytryptamine lesions.
    Porceddu ML; Imperato A; Melis MR; Di Chiara G
    Brain Res; 1983 Mar; 262(2):187-200. PubMed ID: 6404501
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pyrogen fever in rabbits pretreated with p-chlorophenylalanine or 5, 6-dihydroxytryptamine.
    Carruba MO; Bächtold HP
    Experientia; 1976 Jun; 32(6):729-30. PubMed ID: 133031
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of drugs acting on cerebral 5-hydroxytryptamine mechanisms on dopamine-dependent turning behaviour in mice.
    Milson JA; Pycock CJ
    Br J Pharmacol; 1976 Jan; 56(1):77-85. PubMed ID: 130178
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Genetic differences in ethanol drinking of the rat following injection of 6-OHDA, 5,6-DHT or 5,7-DHT into the cerebral ventricles.
    Melchior CL; Myers RD
    Pharmacol Biochem Behav; 1976 Jul; 5(1):63-72. PubMed ID: 996042
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of 5,6-dihydroxytryptamine and 5,7-dihydroxytryptamine on the rat central nervous system after intraventricular or intracerebral application and on blood platelets in vitro.
    Da Prada M; Pieri L; Keller HH; Pieri M; Bonetti EP
    Ann N Y Acad Sci; 1978 Jun; 305():595-620. PubMed ID: 152083
    [No Abstract]   [Full Text] [Related]  

  • 27. Evaluation of the non-specific effects of catecholamine and serotonin neurotoxins by injection into the medial forebrain bundle of the rat.
    Lorden JF; Oltmans GA; Dawson R; Callahan M
    Pharmacol Biochem Behav; 1979 Jan; 10(1):79-86. PubMed ID: 312504
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacology in vivo of the phenylindan derivative, Lu 19-005, a new potent inhibitor of dopamine, noradrenaline and 5-hydroxytryptamine uptake in rat brain.
    Arnt J; Christensen AV; Hyttel J
    Naunyn Schmiedebergs Arch Pharmacol; 1985 Apr; 329(2):101-7. PubMed ID: 2409454
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparative effects of hallucinogenic drugs on rotational behavior in rats with unilateral 6-hydroxydopamine lesions.
    Trulson ME; Stark AD; Jacobs BL
    Eur J Pharmacol; 1977 Jul; 44(2):113-9. PubMed ID: 560306
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hallucinogen-induced rotational behavior in rats.
    Fleisher LN; Glick SD
    Psychopharmacology (Berl); 1979 Apr; 62(2):193-200. PubMed ID: 111284
    [No Abstract]   [Full Text] [Related]  

  • 31. Recovery of brain noradrenaline after 5,7-dihydroxytryptamine-induced axonal lesions in the rat.
    Björklund A; Baumgarten HG; Lachenmayer L; Rosengren E
    Cell Tissue Res; 1975 Aug; 161(2):145-55. PubMed ID: 1175203
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Further studies on the mode of action of psychotomimetic drugs: antagonism of the excitatory actions of 5-hydroxytryptamine by methylated derivatives of tryptamine.
    Bradley PB; Briggs I
    Br J Pharmacol; 1974 Mar; 50(3):345-54. PubMed ID: 4277490
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Behavioral effects of 5, 7-dihydroxytryptamine lesions of ascending 5-hydroxytryptamine pathways.
    Hole K; Fuxe K; Jonsson G
    Brain Res; 1976 May; 107(2):385-99. PubMed ID: 944613
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inhibition by dopamine agonists of dopamine accumulation following gamma-hydroxybutyrate treatment.
    Handforth A; Sourkes TL
    Eur J Pharmacol; 1975 Dec; 34(2):311-9. PubMed ID: 1243993
    [TBL] [Abstract][Full Text] [Related]  

  • 35. LSD as an agonist at mesolimbic dopamine receptors.
    Kelly PH; Iversen LL
    Psychopharmacologia; 1975 Dec; 45(2):221-4. PubMed ID: 2943
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hypokinesia produced by anterolateral hypothalamic 6-hydroxydopamine lesions and its reversal by some antiparkinson drugs.
    Butterworth RF; Bélanger F; Barbeau A
    Pharmacol Biochem Behav; 1978 Jan; 8(1):41-5. PubMed ID: 625480
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of amperozide on induced turning behaviour in 6-OHDA lesioned rats.
    Christensson EG
    Pharmacol Toxicol; 1990; 66 Suppl 1():22-8. PubMed ID: 2106130
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of harmine and brain lesions on apomorphine induced motor activity.
    Westermann KH; Funk K; Pawlowski L
    Pharmacol Biochem Behav; 1976 Jan; 4(1):1-6. PubMed ID: 131324
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Relationship of biogenic amines to behavior.
    Breese GR; Cooper BR; Hollister AS
    J Psychiatr Res; 1974; 11():125-33. PubMed ID: 4282384
    [No Abstract]   [Full Text] [Related]  

  • 40. Disruption of conditioned avoidance behavior by n,n-dimethyltryptamine (DMT) and stereotype by beta-phenylethylamine (PEA): animal models of attentional defects in schizophrenia.
    Stoff DM; Moja EA; Gillin JC; Wyatt RJ
    J Psychiatr Res; 1978; 14(1-4):225-40. PubMed ID: 281530
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.